STOCKHOLM, June 8 (Reuters) - Swedish rare diseases drugmaker Swedish Orphan Biovitrum (Sobi) said on Monday it had terminated discussions regarding a non-binding proposal in relation to a possible offer for the company.
The firm said in late April it had received a preliminary proposal for a bid on the company, and Reuters identified Pfizer as the bidder.
“The Board of Directors of Sobi has terminated discussions regarding this proposal,” Sobi said in a statement.
“Sobi will continue to focus on preparations for the upcoming planned launch of Elocta and Alprolix and on building value through its diverse and growing portfolio.”
Reporting by Johannes Hellstrom; editing by Niklas Pollard